Henghui Zhang

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Venues

Signal transduction and targeted therapy

Cancer immunology, immunotherapy : CII

Current oncology (Toronto, Ont.)

Biomarker research

Beijing Ditan Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Beijing Ditan Hospital

China

professor :: Institute of Infectious Diseases

Genecast Biotechnology Co., Ltd

China

Chief Medical Officer

Publications

Yanni Wang, Chang Liu, Huan Chen, Xi Jiao, Yujiao Wang, Yanshuo Cao, Jian Li, Xiaotian Zhang, Yu Sun, Na Zhuo, Fengxiao Dong, Mengting Gao, Fengyuan Wang, Liyuan Dong, Jifang Gong, Tianqi Sun, Wei Zhu, Henghui Zhang, Lin Shen, Zhihao Lu
Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma. Signal transduction and targeted therapy 9 (1) (2024)
Yanni Wang, Chang Liu, Huan Chen, Xi Jiao, Yujiao Wang, Yanshuo Cao, Jian Li, Xiaotian Zhang, Yu Sun, Na Zhuo, Fengxiao Dong, Mengting Gao, Fengyuan Wang, Liyuan Dong, Jifang Gong, Tianqi Sun, Wei Zhu, Henghui Zhang, Lin Shen, Zhihao Lu
Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma. Signal transduction and targeted therapy 9 (1) (2024)
Yanni Wang, Chang Liu, Huan Chen, Xi Jiao, Yujiao Wang, Yanshuo Cao, Jian Li, Xiaotian Zhang, Yu Sun, Na Zhuo, Fengxiao Dong, Mengting Gao, Fengyuan Wang, Liyuan Dong, Jifang Gong, Tianqi Sun, Wei Zhu, Henghui Zhang, Lin Shen, Zhihao Lu
Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma. Signal transduction and targeted therapy 9 (1) (2024)
Tao Jiang, Qiqi Jin, Jiahao Wang, Feng-Ying Wu, Jian Chen, Gongyan Chen, Yunchao Huang, Jianhua Chen, Ying Cheng, Qi-Ming Wang, Yue-Yin Pan, Jian-Ying Zhou, Jianhua Shi, Xingxiang Xu, LiZhu Lin, Wei Zhang, Yiping Zhang, Yun-Peng Liu, Yong Fang, Jifeng Feng, Zhehai Wang, Sheng Hu, Jian Fang, Yongqian Shu, Jiu-Wei Cui, Yi Hu, Wenxiu Yao, Xingya Li, Xiaoyan Lin, Rui Wang, Yongsheng Wang, Wei Shi, Gaohua Feng, Jun Ni, Beibei Mao, Dandan Ren, Huaibo Sun, Henghui Zhang, Luo-Nan Chen, Cai-Cun Zhou, Shengxiang Ren
HLA-I evolutionary divergence confers response to PD-1 blockade plus chemotherapy in untreated advanced non-small-cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Xueying Wu, Chenyang Zhang, Henghui Zhang
Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer. Current oncology (Toronto, Ont.) 29 (1) (2022)
Shuhang Wang, Pei Yuan, Beibei Mao, Ning Li, Jian-Ming Ying, Xiuli Tao, Wei Tang, Lei Zhang, Xiao Geng, Fan Zhang, Qi Xue, Lijia Wu, Henghui Zhang, Shugeng Gao, Jie He
Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade. NPJ precision oncology 6 (1) (2022)
Fang Lv, Xueying Wu, Jin Song, Pan Wang, Shucheng Ren, Wei Guo, Qi Xue, Henghui Zhang, Jun Zhao
Single cell transcriptome revealed tumor associated antigen (TAA) profile in lung adenocarcinoma (LUAD). Biomarker research 9 (1) (2021)
Chuanhua Zhao, Lihong Wu, Dandan Liang, Huan Chen, Shoujian Ji, Guanxiong Zhang, Keyan Yang, Ying Hu, Beibei Mao, Tianshu Liu, Yiyi Yu, Henghui Zhang, Jianming Xu
Identification of immune checkpoint and cytokine signatures associated with the response to immune checkpoint blockade in gastrointestinal cancers. Cancer immunology, immunotherapy : CII 70 (9) (2021)
Yong Wang, Dandan Liang, Jimin Chen, Huan Chen, Rui Fan, Ye Gao, Yongsheng Gao, Rongjie Tao, Henghui Zhang
Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma. The oncologist 26 (3) (2020)
Lisheng Cai, Linhai Li, Dandan Ren, Xue Song, Beibei Mao, Bo Han, Henghui Zhang
Prognostic impact of gene copy number instability and tumor mutation burden in patients with resectable gastric cancer. Cancer communications (London, England) 40 (1) (2020)

Henghui Zhang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Henghui Zhang